# A3373

| | |
|---|---|
| **Cat. No.:** | HY-155342 |
| **CAS No.:** | 2324948-66-3 |
| **Molecular Formula:** | $C_{17}H_9F_7N_2O$ |
| **Molecular Weight:** | 390.25 |
| **Target:** | Phospholipase |
| **Pathway:** | Metabolic Enzyme/Protease |
| **Storage:** | Powder -20°C 3 years<br>4°C 2 years<br>In solvent -80°C 6 months<br>-20°C 1 month |



## SOLVENT & SOLUBILITY

**In Vitro**

DMSO : 100 mg/mL (256.25 mM; ultrasonic and warming and heat to 60°C)

| Preparing Stock Solutions | Solvent / Mass / Concentration | 1 mg | 5 mg | 10 mg |
|---|---|---|---|---|
| | 1 mM | 2.5625 mL | 12.8123 mL | 25.6246 mL |
| | 5 mM | 0.5125 mL | 2.5625 mL | 5.1249 mL |
| | 10 mM | 0.2562 mL | 1.2812 mL | 2.5625 mL |

Please refer to the solubility information to select the appropriate solvent.

**In Vivo**

1. Add each solvent one by one: 10% DMSO >> 90% corn oil
   Solubility: 5 mg/mL (12.81 mM); Clear solution; Need ultrasonic

## BIOLOGICAL ACTIVITY

**Description**

A3373, a novel chemical inhibitor of Phospholipase D1 (PLD1) and PLD2, with $IC_{50}$ of 325 nM and 15.15?μM, respectively, inhibits LPS-induced immune response and plays important roles in autoimmune arthritis, bone demineralization and osteoclastogenesis[1][2].

| $IC_{50}$ & Target | PLD1 | PLD2 |
|---|---|---|
| | 325 nM ($IC_{50}$) | 15.15 μM ($IC_{50}$) |

## REFERENCES

[1]. Won Chan Hwang, et al. Inhibition of phospholipase D1 induces immunogenic cell death and potentiates cancer immunotherapy in colorectal cancer.Exp Mol Med. 2022 Sep;54(9):1563-1576.

[2]. Jin-Sil Park, et al. A newly developed PLD1 inhibitor ameliorates rheumatoid arthritis by regulating pathogenic T and B cells and inhibiting osteoclast differentiation. Immunol Lett. 2023 Sep 16:263:87-96.



Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA